The first Flexner Discovery Lecture of the academic year featured presentations by two Vanderbilt faculty members.

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

John Karijolich, PhD, assistant professor of Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center, has been named a Pew Biomedical Scholar by The Pew Charitable Trusts.

New research links nutrient-responsive cellular signaling to the antibody-mediated immune response.

Vanderbilt investigators have discovered a role for immune system T cells in slowing the decline in skeletal muscle function in patients with Duchenne muscular dystrophy.

Vanderbilt investigators have discovered a class of compounds that inhibit a mediator of inflammation and autoimmune disorders, and that could pave the way for development of future therapies.